Nancy E. Denyes
2022
In 2022, Nancy E. Denyes earned a total compensation of $857.5K as General Counsel at aTYR PHARMA, a 4% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $126,925 |
|---|---|
| Option Awards | $266,053 |
| Salary | $396,635 |
| Stock Awards | $59,340 |
| Other | $8,575 |
| Total | $857,528 |
Denyes received $396.6K in salary, accounting for 46% of the total pay in 2022.
Denyes also received $126.9K in non-equity incentive plan, $266.1K in option awards, $59.3K in stock awards and $8.6K in other compensation.
Rankings
In 2022, Nancy E. Denyes' compensation ranked 3,356th out of 5,760 executives tracked by ExecPay. In other words, Denyes earned more than 41.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,356 out of 5,760 | 42nd |
Division Manufacturing | 1,896 out of 3,136 | 40th |
Major group Chemicals And Allied Products | 903 out of 1,422 | 37th |
Industry group Drugs | 845 out of 1,323 | 36th |
Industry Biological Products, Except Diagnostic Substances | 203 out of 291 | 30th |
Source: SEC filing on April 5, 2024.
Denyes' colleagues
We found two more compensation records of executives who worked with Nancy E. Denyes at aTYR PHARMA in 2022.